The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported ...

Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised ...

Mechanical engineers have developed a system of artificial cilia capable of monitoring mucus conditions in human airways to better detect infection, airway obstruction, or the severity of diseases ...

for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). “These compelling results support advancing the development of nintedanib DPI for patients living with IPF ...

MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases: Danbury, Connecticut Tuesday, November 5, 2024, 16:00 Hrs [IST] MannKind Corporation, a company ...

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...

South Korean researchers have developed a new technology that can recognize and detect lung diseases such as Chronic ...

Idiopathic pulmonary fibrosis is a chronic, progressive, incurable lung disease, leading to irreversible lung tissue ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...